IBT-B Infant Bacterial Therapeutics AB (publ)
Infant Bacterial Therapeutics AB (publ) operates as a clinical stage pharmaceutical company develops and markets drugs to prevent serious neonatal diseases affecting premature infants in Sweden. The company's lead drug candidate is IBP-9414, which has completed Phase III clinical studies to prevent necrotizing enterocolitis, as well as to improve feeding tolerance in premature infants. It is also developing IBP-1016 for the treatment of gastroschisis, a rare and severe birth abnormality in infants. In addition, its drug candidates include IBP-1118 to prevent retinopathy of prematurity that causes blindness in premature babies; and IBP-1122, indicated to eliminate vancomycin resistant enterococci that cause antibiotic resistant hospital infections. The company was incorporated in 2011 and is headquartered in Stockholm, Sweden.…
Industry Peers
BiotechnologyKey Statistics
About Infant Bacterial Therapeutics (STO: IBT-B)
›
Infant Bacterial Therapeutics (STO: IBT-B) is listed on Nasdaq Stockholm, where its shares trade in SEK. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 6 employees.
The shares were at 69.40 SEK on 20 November 2026, up 18.4% over 52 weeks. Its 52-week range is 43.25 SEK to 84.90 SEK: the price is 18.3% below the high and 60.5% above the low.
Its market capitalisation is 934.92M SEK.
Infant Bacterial Therapeutics reports return on equity of -61.9% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 108.60M SEK. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health.